Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come

Edward B Garon; Phillip A Abarca; Jennifer L Strunck; Danielle Nameth; Catherine Neumann; Brian Wolf; Kevin Y Kim; Caitlin Marx; Robert M Elashoff

doi:10.1615/CritRevOncog.v20.i5-6.70

Back

Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come

Journal article

Open access

Peer reviewed

Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come

Edward B Garon, Phillip A Abarca, Jennifer L Strunck, Danielle Nameth, Catherine Neumann, Brian Wolf, Kevin Y Kim, Caitlin Marx and Robert M Elashoff

Critical reviews in oncogenesis, Vol.20(5-6), pp.339-348

2015

DOI: 10.1615/CritRevOncog.v20.i5-6.70

PMCID: PMC5273860

PMID: 27279233

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/5273860View

Open Access

Abstract

Lung cancer is the leading cause of cancer mortality. Great advances in non-small cell lung cancer therapy have been seen in the last decade, beginning with the success in treating lung cancer harboring EGFR mutations and ALK-gene rearrangements. The potential of these biomarker-driven therapies has propelled research in biomarker targeted approaches to the forefront of lung cancer research. The successful development of immunotherapeutic agents targeting PD-L1 and PD-1 with an associated non-genomic biomarker has opened a new front in the effort for targeted approaches. Although early-phase lung cancer studies have hinted at the potential to use biomarkers to select patients for allocation to treatment in the conduct of clinical trials, data from late-phase studies have tempered expectations. The data leave unclear the wisdom of routinely restricting enrollment on lung cancer clinical trials to biomarker restricted populations, particularly non-genomic biomarkers.

Biomarkers, Tumor - genetics

Carcinoma, Non-Small-Cell Lung - diagnosis

Carcinoma, Non-Small-Cell Lung - genetics

Carcinoma, Non-Small-Cell Lung - metabolism

Carcinoma, Non-Small-Cell Lung - therapy

Clinical Trials as Topic

Humans

Lung Neoplasms - diagnosis

Lung Neoplasms - genetics

Lung Neoplasms - metabolism

Lung Neoplasms - therapy

Mutation

Receptor, Epidermal Growth Factor - genetics

Details

Title: Subtitle: Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come
Creators: Edward B Garon - University of California, Los Angeles
Phillip A Abarca - Keck Hospital of USC
Jennifer L Strunck - University of California, Los Angeles
Danielle Nameth - Tufts University
Catherine Neumann - Boston University
Brian Wolf - Tel Aviv University
Kevin Y Kim - Loma Linda University
Caitlin Marx - Universidad CES
Robert M Elashoff - University of California, Los Angeles
Resource Type: Journal article
Publication Details: Critical reviews in oncogenesis, Vol.20(5-6), pp.339-348
DOI: 10.1615/CritRevOncog.v20.i5-6.70
PMID: 27279233
PMCID: PMC5273860
NLM abbreviation: Crit Rev Oncog
ISSN: 0893-9675
eISSN: 2162-6448
Grant note: K23 CA149079 / NCI NIH HHS
Language: English
Date published: 2015
Academic Unit: Orthopedics and Rehabilitation; Physical Therapy and Rehabilitation Science
Record Identifier: 9984294954302771

Metrics

14 Record Views